|Dr. Maxine Gowen Ph.D.||Chief Exec. Officer, Pres and Exec. Director||784.52k||N/A||60|
|Dr. Michael W. Lark Ph.D.||Chief Scientific Officer & Sr. VP of Research||494.63k||N/A||61|
|Mr. John M. Limongelli Esq.||Chief Admin. Officer, Sr. VP, Gen. Counsel and Corp. Sec.||457.48k||N/A||48|
|Dr. Howard A. Rockman M.D.||Scientific Founder, Consultant and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Roberto E. Cuca J.D.||Chief Financial Officer, Sr. VP and Treasurer||N/A||N/A||50|
Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a ??-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.
Trevena, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 9.